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 Loss of BTG1 potentiates ETV6-RUNX1-mediated self-renewal capacity23
 Tumor suppressor BTG1 limits activation of BCL6 by ETV6-RUNX124
 BCL6 enhances the clonogenicity of primitive B lymphoid progenitors25
26
Abstract27
Translocation t(12;21) (p13;q22), giving rise to the ETV6-RUNX1 fusion gene, is the28
most common genetic abnormality in childhood B-cell precursor acute lymphoblastic29
leukemia (BCP-ALL). This translocation usually arises in utero, but its expression is30
insufficient to induce leukemia and requires other cooperating genetic lesions for31
BCP-ALL to develop. Deletions affecting the transcriptional coregulator BTG1 are32
frequently observed in ETV6-RUNX1-positive leukemia. Here we show that Btg133
deficiency enhances the self-renewal capacity of ETV6-RUNX1 positive mouse fetal34
liver derived hematopoietic progenitors (FL-HPCs). Combined expression of the35
fusion protein and a loss of BTG1 drives upregulation of the proto-oncogene Bcl6 and36
downregulation of BCL6 target genes, such as p19Arf and Tp53. Similarly, ectopic37
expression of BCL6 promotes the self-renewal and clonogenic replating capacity of38
FL-HPCs, by suppressing the expression of p19Arf and Tp53.39
Together these results identify BCL6 as a potential driver of ETV6-RUNX1 mediated40




B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy in45
children and characterized by the presence of distinct genetic abnormalities. The t(12;21)46
(p13;q22) chromosomal translocation arises in utero, giving rise to ETV6-RUNX1 fusion47
protein, generating a preleukemic clone, which requires additional cooperating events before48
3overt leukemia develops [1, 2]. Genomic profiling of ETV6-RUNX1-positive BCP-ALL has49
identified recurrent copy number aberrations (CNAs), including deletions affecting B-cell50
translocation gene 1 (BTG1) [3, 4]. We and others have shown that monoallelic BTG151
deletions in ETV6-RUNX1-positive BCP-ALL are the result of genomic rearrangements52
mediated by aberrant RAG recombinase activity [5, 6]. Focal deletions affecting BTG1 are53
present in 9% of all BCP-ALL cases, but are enriched to about 20% in ETV6-RUNX1-positive54
leukemia, without affecting patient outcome [3, 4, 6, 7]. BTG1 functions as a transcriptional55
cofactor that acts by recruiting effector molecules, such as the protein arginine56
methyltransferase I (PRMT1) to specific transcription factors, thus affecting proliferation and57
differentiation [8, 9]. In this paper, we investigated if loss of BTG1 affects the self-renewal58
capacity of ETV6-RUNX1 in mouse fetal liver hematopoietic progenitor cells (FL-HPCs) by59





The generation of C57BL/6J Btg1 knockout (KO) mice has been previously described by65
Farioli-Vecchiolo et al. [10]. The animals were maintained under specific pathogen-free66
conditions at our animal facility. All animal experiments were approved by the Animal67
Experimental Committee of the Radboud university medical center and were performed in68
accordance with institutional and national guidelines. For the retroviral transduction69
experiments, fetal liver cells derived from day 13.5 of wild-type and Btg1-/- embryos were70
used.71
72
Retroviral transduction of fetal liver-derived progenitor cells and adult bone marrow73
Primitive fetal liver hematopoietic progenitor cells (FL-HPCs) were purified as c-Kit+Ter119-74
cells from fetal livers of embryonic day 13.5 (E13.5) of C57Bl6/J wild-type and Btg1-/- mice by75
MACS sort using Ter119 and cKit (CD117) beads (Miltenyi Biotec). FL-HPCs were expanded76
4in Iscoves modified Dulbecco medium (IMDM) (Gibco) supplemented with 10% fetal-bovine77
serum (FBS) (Greiner Bio-One), 1% Penicillin-Streptomycin (Invitrogen) and 55µM 2-ME78
(Gibco) in the presence of 10ng/ml fms-like tyrosine kinase-3 ligand (Flt-3L), 20ng/ml79
Interleukin 7 (IL-7) ( and 100ng/ml stem cell factor (SCF) (all R&D) for 24 hours. Cells were80
transduced with retrovirus by spinoculation for 45 min at 700xg (25°C) in the presence of81
5µg/ml polybrene and cultured with the same growth factors for 48 hours, as has been82
described by Morrow et al. [11]. CD19+ bone marrow cells were purified from 10 weeks old83
wild-type and Btg1-/- mice by MACS sorting using CD19 beads (Miltenyi Biotec). CD19+ cells84
were cultured in improved minimal essential medium (IMEM) (Gibco) supplemented with 2%85
FBS (Greiner Bio-One), 1% Penicillin-Streptomycin (Invitrogen), 0.03% primatone and 55µM86
2-ME in the presence of 20ng/ml IL-7 (R&D) on OP9 stroma for 48 hours. Cells were87
transduced by spinoculation (45 min at 700xg, 25°C) in the presence of 10µg/ml protamine88
sulphate and cultured in the same pro-B cell medium for 24 hours. Transduction efficiency89




Transduced FL-HPCs (1x104 cells/plate) and CD19+ bone marrow cells (1x105 cells/plate)94
derived of wild-type and Btg1-/- animals, were cultured in duplicate methylcellulose cultures95
using 35mm plates (M3630, STEMCELL Technologies), 48 hours after viral transduction.96
The FL-HPC methylcellulose cultures were supplemented with 10ng/ml FLT3L, 20ng/ml IL-797
and 100ng/ml SCF . After 6-10 days, colonies (>30 cells) were scored, pooled and counted.98
Replating of 1x104 cells/plate was performed under identical conditions.99
100
Results and discussion101
To examine contribution of BTG1 loss to ETV6-RUNX1 positive ALL, we compared in vitro102
self-renewal capacity of wild-type and Btg1-deficient FL-HPCs. Therefore, FL-HPCs isolated103
from C57Bl/6J wild-type and Btg1-/- embryos at 13.5 days post coitum (dpc) were transduced104
5with either control or ETV6-RUNX1 retrovirus and propagated in B-lineage promoting culture105
conditions. Transduction was observed in 40%-70% of both wild-type and Btg1-/- FL-HPCs by106
flow cytometry and confirmed by western blot analysis (Supplementary Figure E1). Wild-type107
and Btg1-/- FL-HPCs transduced with either control or ETV6-RUNX1 virus were cultured in108
methylcellulose containing cytokines to facilitate expansion and differentiation of early B cell109
progenitors. Subsequently, cells were analyzed for their ability to maintain self-renewal110
capacity by serial replating assays. We observed that introduction of the ETV6-RUNX1111
fusion protein enhanced self-renewal capacity, particularly in a Btg1-deficient background112
(Fig. 1A). However, transformation to a full leukemia in vivo by transplantation of ETV6-113
RUNX1 transduced wild-type and Btg1-/- HPCs was not observed (results not shown). These114
data suggest that BTG1 function limits the ETV6-RUNX1-mediated self-renewal capacity of115
colony-forming fetal progenitor B-cells, but that loss of Btg1 is not sufficient to drive116
leukemogenesis in this experimental model.117
To determine whether this phenotype could also be observed in adult-type B cell118
progenitors, we examined the effect of ETV6-RUNX1 expression in CD19+-purified adult119
bone marrow cells, derived from wild-type or Btg1-/- mice. Consistent with previous reports120
[12], ETV6-RUNX1 suppressed colony formation of adult progenitor B-cells, which was121
further enhanced in the absence of BTG1 (Supplementary Figure E2). These findings are122
consistent with the notion that ETV6-RUNX1-mediated leukemic transformation occurs123
primarily in the developing embryo and not in adult progenitor B-cells.124
To elucidate the molecular mechanism by which Btg1 deficiency enhances ETV6-125
RUNX1-induced self-renewal capacity of FL-derived progenitor B-cells, we performed gene126
expression analysis of FL-HPCs cultured in our standard cytokine-containing medium. Gene127
Set Enrichment Analysis (GSEA) was performed to define KEGG pathways that were128
specifically affected by ETV6-RUNX1 expression in the two different genetic backgrounds129
(Fig. 1B and Supplementary Table E1). Interestingly, we identified a p53 signature in both130
wild-type and Btg1-/- FL-HPCs in the presence of ETV6-RUNX1 expression, which involved131
downregulation of p53 target genes Cdkn2a, Gadd45g and CcnD2 expression132
6(Supplementary Table E1). As we observed reduced expression of Tp53 in ETV6-133
RUNX1;Btg1-/- fetal progenitor B-cells, we hypothesized that an upstream regulator of the134
p53 pathway might be affected in these cells. Notably, we observed a 4-fold upregulation of135
Bcl6 mRNA levels in ETV6-RUNX1-positive Btg1-deficient fetal progenitor B-cells relative to136
control cells. By qRT-PCR we validated that Bcl6 expression was induced in ETV6-137
RUNX1;Btg1-/- pro-B cells, accompanied by repression of known BCL6 target genes such as138
p19Arf, Tp53, CcnD2, Bcl2 and c-Myc (Fig. 1C). However, due to poor quality of the139
available antibodies, we were unable to detect native BCL6 protein in these fetal liver cells.140
As p53 is subject to regulation of the E3 ubiquitin-protein ligase MDM2, and ETV6-141
RUNX1 has been shown to activate MDM2 expression [13], we examined Mdm2 mRNA142
expression in these FL-HPCs. However, no significant differences in expression of Mdm2143
were found (Fig. 1C). By western blot analysis we confirmed that p53 protein levels were144
reduced in ETV6-RUNX1-positive fetal progenitor B-cells relative to control and Btg1-/- cells,145
while expression was even further reduced in ETV6-RUNX1;Btg1-/- pro-B-cells (Fig. 1D).146
These data demonstrate that BTG1 loss synergizes with ETV6-RUNX1 in activating BCL6147
expression and repression of its downstream targets such as Tp53 and p19Arf.148
To study whether increased BCL6 expression itself was responsible for the enhanced149
self-renewal capacity observed in ETV6-RUNX1-positive Btg1-/- FL-HPCs, we transduced150
wild-type FL-derived progenitor B-cells with either control or BCL6 retrovirus. Flow cytometric151
analysis showed a transduction efficiency of 30%-50% GFP-positive cells (data not shown).152
Indeed, forced expression of BCL6 efficiently promoted the clonogenic replating capacity of153
FL-HPCs to a similar extent as observed in ETV6-RUNX1;Btg1-/- cells (Fig. 2A). Gene154
expression analyses by qRT-PCR revealed a significant reduction in p19Arf and Tp53155
expression, which mirrored the phenotype observed in ETV6-RUNX1;Btg1-/- fetal progenitor156
B-cells (Fig. 2B). Western blot analysis confirmed that p53 protein levels were decreased in157
BCL6 transduced fetal pro-B-cells (Fig. 2C). These results indicate that BCL6 enhances the158
clonogenicity of primitive B lymphoid progenitors, which is in sharp contrast to its effects on159
adult definitive precursor B-cells [14].160
7Previous studies have shown that RUNX1 is methylated by the arginine161
methyltransferase PRMT1 [15-17] and that BTG1 acts by recruiting and stimulating the162
enzymatic activity of PRMT1 [8, 9, 18]. Consistent with these findings, we could demonstrate163
that ETV6-RUNX1 associates with both BTG1 and PRMT1 when co-expressed in HEK293164
cells (Fig. 3A-B). In addition, by performing PRMT1 co-immunoprecipitation in control and165
Btg1-/- FL-HPCs protein lysates, we observed that BTG1 is required for the association166
between ETV6-RUNX1 and PRMT1 (Fig. 3C). However, how modulation of ETV6-RUNX1167
function by the BTG1-PRMT1 complex affects expression of BCL6 remains to be explored.168
BCL6 has been identified as a critical determinant of leukemic stem cell survival in169
chronic myeloid leukemia (CML) and BCR-ABL1-positive ALL, involving repression of170
p14ARF and TP53 [14, 19]. Previous reports have shown that the RUNX1 fusion protein171
AML1-ETO, an important driver of acute myeloid leukemia, represses transcription of172
p14ARF [20]. Our study shows that downstream targets of BCL6, including p19Arf and Tp53,173
are downregulated in ETV6-RUNX1-positive fetal progenitor B-cells, particularly in the174
absence of BTG1 function. Furthermore, ectopic expression of BCL6 in primitive progenitor175
B-cells induced a similar proliferative expansion, accompanied by downregulation of TP53176
and p19Arf expression. These data indicate that BCL6 promotes proliferation of primitive B177
lymphoid progenitors by suppressing the p53 pathway. Future studies will need to establish178
whether inhibition of BCL6 could be effective in the eradication of leukemia-initiating cells in179
ETV6-RUNX1-positive ALL.180
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Figure 1. BTG1 loss enhances self-renewal of ETV6-RUNX1-positive fetal progenitor B-cells252
by activation of BCL6 pathway. (A-D) Fetal liver-derived hematopoietic progenitor cells (FL-253
HPCs) were isolated from wild-type (WT) and Btg1-/- embryos at day 13.5dpc and transduced254
with control and ETV6-RUNX1 retrovirus. (A) Control and ETV6-RUNX1 transduced FL-255
HPCs (1x104 cells) were seeded 48 hours after transduction in duplicate in B cell specific256
methylcellulose supplemented with FLT3L, IL-7 and SCF. Serial replating was performed257
under identical conditions. Mean colony counts (and SEM) were determined (>30258
cells/colony) after 6-10 days of culture. Data set is representative of 2 independent259
experiments. *, P< 0.05, **, P< 0.01. (B) Gene set enrichment analyses on gene expression260
data of WT, ETV6-RUNX1, Btg1-/- and ETV6-RUNX1;Btg1-/- fetal progenitor B-cells. Total261
RNA was extracted from FL-HPCs, which were expanded for 12 days in liquid medium262
supplemented with FLT-3L, IL-7 and SCF. The data were RMA normalized and relative gene263
expression differences of >1.6-fold were included. KEGG pathway analysis was performed264
using the online Gene Set Enrichment Analysis (GSEA) tool and relevant pathways that are265
differentially expressed between wild-type and ETV6-RUNX1 as well ETV6-RUNX1;Btg1-/-266
FL cells are indicated. (C) Relative expression levels of Bcl6, Tp53, p19Arf, Mdm2, CcnD1,267
CcnD2, Bcl2 and c-Myc were determined by quantitative reverse-transcription PCR (qRT-268
PCR) and normalized to the expression of the housekeeping gene TATA box binding protein269
(TBP). Data represent the mean and SEM of three independent experiments. *, P< 0.05, **,270
P< 0.01, ***, P< 0.001. (D) Protein lysates were generated from FL-HPCs that were271
10
expanded for 12 days in liquid medium supplemented with FLT-3L, IL-7 and SCF. The272
immunoblot demonstrates expression of p53, while β-actin serves as a loading control. 273
Quantitation of relative expression levels is indicated.274
275
Figure 2. BCL6 stimulates self-renewal of early B cell progenitors. (A-C) Fetal liver-derived276
hematopoietic progenitor cells (FL-HPCs) were isolated from wild-type embryos at day277
13.5dpc and transduced with control or BCL6 retrovirus. (A) Control and BCL6 transduced278
FL-HPCs (1x104 cells) were cultured 48 hours after transduction in B cell specific279
methylcellulose supplemented with FLT-3L, IL-7 and SCF. Serial replating was performed280
under identical conditions. Mean colony counts (and SEM) were determined (>30281
cells/colony) after 6-10 days of culture. Data set is representative of 2 independent282
experiments. **, P< 0.01. (B) RNA was isolated from FL-HPCs that were expanded for 10283
days in liquid cultures in the presence of cytokines FLT-3L, IL-7 and SCF. Relative284
expression levels of Tp53, p19Arf, Mdm2, CcnD1, CcnD2, Bcl2 and c-Myc were determined285
on cDNA generated from transduced wild-type FL progenitor cells by real-time PCR and286
normalized to TBP. Data represent the mean and SEM of three independent experiments. *,287
P< 0.05, **, P< 0.01, ***, P< 0.001. (C) Protein lysates were generated from FL-HPCs that288
were expanded for 13 days in liquid cultures in the presence of cytokines FLT-3L, IL-7 and289
SCF. The immunoblot shows expression of p53 and the loading control β-actin. Quantitation 290
of relative expression levels is indicated.291
292
Figure 3. ETV6-RUNX1 interacts with PRMT1 and its cofactor BTG1. (A) HEK293 cells were293
transfected with expression plasmids encoding HA-ETV6-RUNX1 and FLAG-BTG1 and294
treated for 16 hours with 5µM of the proteasome inhibitor MG132. Protein lysates were295
generated and subjected to immunoprecipitation (IP) by incubation with FLAG antibody (Ab).296
Immunoblot demonstrates the expression of BTG1 using a FLAG-Ab and ETV6-RUNX1 with297
a HA-Ab in whole cell extracts (WCE) and IP samples. (B) HEK293 cells were transfected298
11
with expression plasmids encoding HA-ETV6-RUNX1 and PRMT1 and treated for 16 hours299
with 5µM of the proteasome inhibitor MG132. Protein lysates were subjected to IP using HA-300
Ab. The immunblot shows expression of PRMT1 using a PRMT1-Ab and ETV6-RUNX1 with301
a HA-Ab in WCE and IP. (C) FL-HPCs (cKit+Ter119-) were isolated from wild-type and Btg1-/-302
embryos at day 13.5dpc and transduced with control and ETV6-RUNX1 virus. Protein lysates303
were generated from FL-HPCs that were expanded for 12 days in liquid cultures in the304
presence of cytokines FLT-3L, IL-7 and SCF and subjected to IP using PRMT1 Ab. The305
immunoblot shows expression of PRMT1 using a PRMT1-Ab and HA-ETV6-RUNX1 using an306
HA-Ab in WCE and IP from wild-type FL cells.307
308
